The Seattle biotech Omeros (OMER) has long told investors it has a potential blockbuster on its hands in OMS721, an experimental drug aimed at treating patients with rare blood and kidney diseases.
So why won’t the company answer questions about its clinical data?
I’ve been trying for months to get answers on key points: How many patients have been dosed with the drug in clinical trials? And is there any proof at all that the drug can be administered via subcutaneous injection, rather than intravenous drip — which is a key selling point for Omeros?
The doyle report has been determined to be untrue in a court of law.
Comments are closed.